Novartis AG (NVS)
| Market Cap | 292.89B +15.1% |
| Revenue (ttm) | 56.69B +2.7% |
| Net Income | 12.76B -6.6% |
| EPS | 6.45 -3.4% |
| Shares Out | 1.90B |
| PE Ratio | 23.84 |
| Forward PE | 16.11 |
| Dividend | $3.08 (2.00%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 2,816,388 |
| Open | 153.53 |
| Previous Close | 151.12 |
| Day's Range | 152.02 - 154.24 |
| 52-Week Range | 121.57 - 170.46 |
| Beta | 0.47 |
| Analysts | Hold |
| Price Target | 154.65 (+0.55%) |
| Earnings Date | Oct 27, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia ... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $154.65, which is an increase of 0.55% from the latest price.
News
Novartis AG Earnings release: Q3 2026
Novartis AG released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Novartis AG Slides: Q3 2026
Novartis AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 27, 2026.
Novartis AG Quarterly report: Q3 2026
Novartis AG has published its Q3 2026 quarterly earnings report on October 27, 2026.
Novartis reports Q3 core EPS $2.46 vs. $2.25 last year
Reports Q3 net sales $14.5B vs. $13.9B last year. Commenting on Q3 2026 results, Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered solid sales growth in Q3, as priority…
Novartis (NVS) Shares Rise 3.1% on Upgraded Core Operating Income Outlook
Novartis (NVS) Shares Rise 3.1% on Upgraded Core Operating Income Outlook
Novartis CEO says company must stay 'courageous' to pursue breakthroughs
Novartis CEO Vas Narasimhan tells CNBC the company must keep pursuing acquisitions that could deliver breakthroughs for patients.
Novartis CEO says AI has tangibly improved P&L for the first time
Novartis CEO, Vas Narasimhan, discusses how AI is beginning to impact the company’s operations. Narasimhan was speaking to CNBC's Carolin Roth around the company's third quarter earnings, a day after ...
Novartis Q3 Profit Sinks 70% Despite Sales Growth; Lifts FY26 Core Income View, Backs Sales Outlook
(RTTNews) - Novartis AG (NVS) reported Tuesday a sharp decline in third-quarter profit, reflecting an impairment charge and higher interest expense, despite increased sales.
Novartis (NVS) Q3 2026 Results Highlight Dividend Sustainability Amid Modest Overvaluation
Novartis (NVS) Q3 2026 Results Highlight Dividend Sustainability Amid Modest Overvaluation
Novartis Adjusts Earnings Outlook Amid Strong Demand for Key Drugs
Novartis Adjusts Earnings Outlook Amid Strong Demand for Key Drugs
Novartis (NVS) Reports Q3 Earnings Amid Strong Drug Sales and Impairment Charges
Novartis (NVS) Reports Q3 Earnings Amid Strong Drug Sales and Impairment Charges
Novartis Raises Guidance Despite Trial Setbacks Hitting Profit
The Swiss drugmaker cited solid sales growth and productivity gains, even as recent clinical-trial setbacks hit its bottom line in the third quarter.
Novartis Q3 Profit Declines; Lifts FY26 Core Income View, Backs Sales Outlook
(RTTNews) - Swiss drug major Novartis AG (NVS, NOVN.SW) reported Tuesday sharply lower profit in its third quarter, mainly hurt by an impairment charge and higher expenses, despite growth in net sales...
Novartis raises full year core operating income guidance
Novartis raised its full-year core operating income guidance on Tuesday after strong third-quarter demand for its key cancer and multiple sclerosis drugs.
Top Analyst Reports for Intel, Novartis & Itau Unibanco
Intel's manufacturing recovery and AI expansion, Novartis' growth drugs and Itau Unibanco's strategic moves headline today's top analyst reports.
Earnings To Watch: Novartis AG (XSWX:NOVN) Q3 2026 -- GF Value Sees 8% Downside
Earnings To Watch: Novartis AG (XSWX:NOVN) Q3 2026 -- GF Value Sees 8% Downside
Novartis AG Remibrutinib in MS Investor Call Transcript
Novartis AG Remibrutinib in MS Investor Call Transcript
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity
Novartis NYSE: NVS presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton's tyrosine kinase inhibitor reduced relapse rates and MRI lesion activit...
Novartis AG Transcript: Investor update
REMODEL-1 and -2 showed lower relapse and MRI activity, with a significant 6-month disability-progression benefit and a favorable reported safety profile. Management sees $4bn-plus RMS potential, with further SPMS upside and broader pipeline opportunities.
Novartis AG Slides: Investor update
Novartis AG has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
Novartis AG (NVS) Stock Down 3.3% but Still Overvalued -- GF Score: 75/100
Novartis AG (NVS) Stock Down 3.3% but Still Overvalued -- GF Score: 75/100
Novartis (NVS) Reports Positive Phase 3 Trial Results for Multiple Sclerosis Treatment Remibrutinib
Novartis (NVS) Reports Positive Phase 3 Trial Results for Multiple Sclerosis Treatment Remibrutinib
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Swiss drugmaker Novartis' oral multiple sclerosis (MS) drug remibrutinib meaningfully reduced relapses in patients, according to data presented at a medical conference in Toronto on Friday, but less ...
Novartis says remibrutinib showed comprehensive disease control in Phase 3 trial
Novartis (NVS) presented positive results from the pivotal Phase 3 REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis, showing that remibrutinib, a highly selective and efficacious oral Br...
Novartis' Kisqali reduces risk of death by 19.1% in 6-year breast cancer study
Novartis reported positive 6-year trial results for its breast cancer drug, Kisqali, showing improved survival rates of 19.1% and lasting benefits from treatment.